You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,958,764


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,958,764
Title: Specific expression vectors and methods of use
Abstract:Gene therapy by using specific expression vectors within the epidermis or epidermal cells. These vectors incorporate regulatory sequences of tissue and differentiation-specific genes.
Inventor(s): Roop; Dennis R. (Houston, TX), Rothnagel; Joseph A. (Houston, TX), Greenhalgh; David A. (Houston, TX)
Assignee: Baylor College of Medicine (Houston, TX)
Application Number:08/146,930
Patent Claims:1. A vector for expression of a nucleic acid sequence in an epidermal cell, wherein said nucleic acid sequence is other than a mammalian loricrin gene or a mammalian K6 keratin gene, said vector comprising, in operable association:

a 5' flanking region from a mammalian gene including necessary sequences for expression of said nucleic acid sequence;

a 3' flanking region from a mammalian loricrin gene or a mammalian K6 keratin gene which regulates expression predominantly in an epidermal cell of said nucleic acid sequence with which it is associated; and

a linker connecting said 5' flanking region to said nucleic sequence, said linker having a position for inserting said nucleic acid sequence, wherein said linker lacks the coding sequences of a gene with which it is naturally associated.

2. The vector of claim 1, wherein said 3' flanking region is 3' to said position for inserting said nucleic acid sequence.

3. The vector of claim 1, wherein said 3' flanking region is 5' to said linker.

4. The vector of claim 1, wherein said vector further comprises a nucleic acid sequence.

5. The vector of claim 1 or 4, wherein said 5' flanking region includes a promoter, a TATA box, a CAP site and a first intron and intron/exon boundary in appropriate relationship for expression of said nucleic acid sequence.

6. The vector of claim 5, wherein said 5' flanking region contains a 5' UTR, and said 3' flanking region contains a 3' UTR and 3' NCR.

7. The vector of claim 1 or 4, wherein said 3' flanking region is from a loricrin gene.

8. The vector of claim 1 or 4, wherein said 5' flanking region and said 3' flanking region are from a loricrin gene.

9. The vector of claim 5, wherein said 5' flanking region is approximately 1.5 kb, said intron and intron/exon boundary is approximately 1.1 kb and said 3' flanking region is approximately 2.1 kb of a loricrin gene.

10. The vector of claim 1 or 4, wherein said 3' flanking region is from a K6 keratin gene.

11. The vector of claim 1 or 4, wherein said 5' flanking region and said 3' flanking region are from a K6 keratin gene.

12. The vector of claim 5, wherein said 5' flanking region is approximately 8.0 kb, said intron and intron/exon boundary is approximately 0.56 kb and said 3' flanking region is approximately 1.2 kb of a K6 keratin gene.

13. The vector of claim 4, wherein said nucleic acid sequence comprises genetic material coding for a protein or a polypeptide.

14. The vector of claim 13, wherein said genetic material codes for a hormone, a growth factor, an enzyme, a clotting factor, an apolipoprotein, a receptor, a drug or an antigen.

15. The vector of claim 5, wherein said 5' flanking region comprises nucleotides 1 to 1540 of Sequence ID No. 1;

said intron and intron/exon boundary comprises nucleotides 1587 to 1679 of Sequence ID No. 1;

said 3' flanking region comprises nucleotides 4384 to 6530 of Sequence ID No. 1; and

said linker inserted at the unique Cla I site at nucleotides 2700 to 2705 of Sequence ID No. 2.

16. The vector of claim 5, wherein said 5' flanking region comprises a unique 5' Xho I site up to nucleotide 360 of Sequence ID No. 3;

said intron and intron/exon boundary comprises nucleotides 928 to 1494 of Sequence ID No. 3;

said 3' flanking region comprises from nucleotide 4740 of Sequence ID No. 3 to a unique 3' Xho I site; and

said linker inserted between nucleotides 1504 to 1509 of Sequence ID No. 3.

17. The vector of claim 1 or 4, wherein said vector further comprises a vitamin D regulatory element associated with said 3' or 5' flanking regions.

18. The vector of claim 17, wherein said vitamin D regulatory element is from a K1 keratin gene.

19. The vector of claim 1 or 4, wherein said vector further comprises a vitamin A regulatory element associated with said 3' or 5' flanking regions.

20. An isolated or cultured mammalian epidermal cell transformed with a vector for expression of a nucleic acid sequence, wherein said nucleic acid sequence is other than a mammalian loricrin gene or a mammalian K6 keratin gene, said vector comprising, in operable association:

a 5' flanking region from a mammalian gene including necessary sequences for expression of said nucleic acid sequence;

a 3' flanking region from a mammalian loricrin gene or a mammalian K6 keratin gene which regulates expression predominantly in an epidermal cell of said nucleic acid sequence with which it is associated; and

a linker connecting said 5' flanking region to said nucleic sequence, said linker having a position for inserting said nucleic acid sequence, wherein said linker lacks the coding sequences of a gene with which it is naturally associated.

21. The mammalian epidermal cell of claim 20, wherein said nucleic acid sequence comprises genetic material coding for a protein or a polypeptide.

22. The mammalian epidermal cell of claim 21, wherein said genetic material codes for a hormone, a growth factor, an enzyme, a clotting factor, an apolipoprotein, a receptor, a drug or an antigen.

23. The mammalian epidermal cell of claim 20, wherein said vector further comprises a vitamin D regulatory element.

24. The mammalian epidermal cell of claim 20, wherein said vector further comprises a vitamin A regulatory element.

Details for Patent 5,958,764

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2016-09-28
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2016-09-28
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2016-09-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.